307 related articles for article (PubMed ID: 15777339)
1. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R
Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339
[TBL] [Abstract][Full Text] [Related]
2. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
[TBL] [Abstract][Full Text] [Related]
3. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
4. Commercial LightCycler-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma.
Kornacker M; Kornacker B; Schmitt C; Leo E; Ho AD; Hensel M
Ann Hematol; 2009 Jan; 88(1):43-50. PubMed ID: 18636259
[TBL] [Abstract][Full Text] [Related]
5. [Practical aspects and clinical value of t(14;18) monitoring in peripheral blood of the follicular lymphoma patients].
Janíková-Oborilová A; Mayer J; Dvorákova D; Mejstrík P; Navritíl M; Vásová I; Kren L; Matuska M
Cas Lek Cesk; 2007; 146(4):374-81; discussion 381-2. PubMed ID: 17491248
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.
Ha CS; Cabanillas F; Lee MS; Tucker SL; McLaughlin P; Rodriguez MA; Younes A; Romaguera JE; Mesina OM; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):188-93. PubMed ID: 16111588
[TBL] [Abstract][Full Text] [Related]
7. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
[TBL] [Abstract][Full Text] [Related]
8. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
9. Detection of t(14;18) by PCR of IgH/BCL2 fusion gene in follicular lymphoma from archived cytological smears.
Stoos-Veić T; Livun A; Ajduković R; Pejsa V; Jaksić O; Kusec R
Coll Antropol; 2010 Jun; 34(2):425-9. PubMed ID: 20698113
[TBL] [Abstract][Full Text] [Related]
10. Use of the polymerase chain reaction and direct sequencing analysis to detect cells with the t(14;18) in autologous bone marrow from patients with follicular lymphoma, before and after in vitro treatment.
Pappa VI; Wilkes S; Salam A; Young BD; Lister TA; Rohatiner AZ
Bone Marrow Transplant; 1998 Sep; 22(6):553-8. PubMed ID: 9758342
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of circulating t(14;18)-positive cells during first-line and subsequent lines of treatment in follicular lymphoma.
Mandigers CM; Meijerink JP; van 't Veer MB; Mensink EJ; Raemaekers JM
Ann Hematol; 2003 Dec; 82(12):743-9. PubMed ID: 14513290
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
[TBL] [Abstract][Full Text] [Related]
13. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy.
Blystad AK; Delabie J; Kvaløy S; Holte H; Vålerhaugen H; Ikonomou I; Kvalheim G
Br J Haematol; 2004 Jun; 125(5):605-12. PubMed ID: 15147376
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of real-time PCR in long-term follow-up of follicular lymphoma patients.
Tysarowski A; Fabisiewicz A; Paszkiewicz-Kozik E; Kulik J; Walewski J; Siedlecki JA
Acta Biochim Pol; 2007; 54(1):135-42. PubMed ID: 17351675
[TBL] [Abstract][Full Text] [Related]
15. A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma.
Arcaini L; Orlandi E; Alessandrino EP; Iacona I; Brusamolino E; Bonfichi M; Bernasconi P; Calatroni S; Tenore A; Montanari F; Troletti D; Pascutto C; Regazzi M; Lazzarino M
Bone Marrow Transplant; 2004 Jul; 34(2):175-9. PubMed ID: 15170171
[TBL] [Abstract][Full Text] [Related]
16. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab.
Galimberti S; Guerrini F; Morabito F; Palumbo GA; Di Raimondo F; Papineschi F; Caracciolo F; Fazzi R; Cervetti G; Cuzzocrea A; Petrini M
Bone Marrow Transplant; 2003 Jul; 32(1):57-63. PubMed ID: 12815479
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
18. The implication of follicular lymphoma patients receiving allogeneic stem cell transplantation from donors carrying t(14;18)-positive cells.
McGregor DK; Keever-Taylor CA; Bredeson C; Schur B; Vesole DH; Logan B; Chang CC
Bone Marrow Transplant; 2005 Jun; 35(11):1049-54. PubMed ID: 15821762
[TBL] [Abstract][Full Text] [Related]
19. The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity.
Schmitt C; Balogh B; Grundt A; Buchholtz C; Leo A; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Jun; 30(6):745-50. PubMed ID: 16297448
[TBL] [Abstract][Full Text] [Related]
20. Quantitative detection of t(14;18)-positive cells in patients with follicular lymphoma before and after autologous bone marrow transplantation.
Hirt C; Dölken G
Bone Marrow Transplant; 2000 Feb; 25(4):419-26. PubMed ID: 10723586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
